SCHEMBL21847178

SCHEMBL21847178

CC(=O)Nc1ccc(C2=NN(Cc3cccnc3)c3nnc(C)n3-c3sc(C)c(CO)c32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 8/20 0.41
NAMPT P43490 3/20 0.39
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
KDM4E B2RXH2 1/20 0.37
TSHR P16473 1/20 0.37
BRCA1 P38398 1/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
PKM P14618 1/20 0.35
MDM2 Q00987 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CCNE2 O96020 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21847204 0.91 BRD4 (0.49) BRD4NAMPTBRD2BRD3
SCHEMBL21847151 0.89 BRD4 (0.41) BRD4NAMPTALDH1A1HTTKDM4E
SCHEMBL21847181 0.87 BRD4 (0.36) BRD4NAMPTBRD2BRD3
SCHEMBL21847169 0.86 BRD4 (0.42) BRD4NAMPTALDH1A1HTTKDM4E
SCHEMBL21847210 0.83 NPC1 (0.37) BRD4NAMPTALDH1A1HTTKDM4E
SCHEMBL21847270 0.83 BRD4 (0.50) BRD4NAMPTBRD2BRD3
SCHEMBL21847212 0.80 ALDH1A1 (0.39) NAMPTALDH1A1HTTKDM4EMAPT
SCHEMBL21847268 0.80 BRD4 (0.46) BRD4NAMPTBRD2BRD3
SCHEMBL21847103 0.79 BRD4 (0.43) BRD4NAMPTBRD2BRD3
SCHEMBL21847132 0.78 BRD4 (0.48) BRD4NAMPTBRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US claimed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US claimed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP claimed
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE BRD4, BRD3, BRD2 BRD4 1/4885NAMPT 2539/4885ALDH1A1 3279/4885
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative BRD4, BRD3, BRD2 BRD4 1/4885NAMPT 2539/4885ALDH1A1 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.